23-Oct-2019 | Zion Market Research
Zion Market Research has published a new report titled “Cancer Supportive Care Drugs Market by Drug Class (Granulocyte-Colony Stimulating Factors (G-CSF), Erythropoietin-Stimulating Agents (ESA), Antiemetics, Bisphosphonates, Opioids, Non-Steroidal Anti-Inflammatory Drugs (NSAID), and Others), and by Cancer Type (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Other Cancers): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025”. According to the report, global demand for cancer supportive care drugs market was valued at approximately USD 21.4 billion in 2018, and is expected to generate revenue of around USD 27.2 billion by end of 2025, growing at a CAGR of around 15.9% between 2019 and 2025.
Browse the full “Cancer Supportive Care Drugs Market: by Drug Class (Granulocyte-Colony Stimulating Factors (G-CSF), Erythropoietin-Stimulating Agents (ESA), Antiemetics, Bisphosphonates, Opioids, Non-Steroidal Anti-Inflammatory Drugs (NSAID), and Others), and by Cancer Type (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Other Cancers): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025” Report at https://www.zionmarketresearch.com/report/cancer-supportive-care-drugs-market
Treatment in cancer causes many side effects like fatigue, pain, menopausal symptoms for women, lymphoedema, cognitive changes, loss of self-esteem and confidence, depression, changes in sexuality, fertility problems, and many other side effects as such. Some of these side effects are serious based on medical condition of the patient which needs urgent treatment while others are upsetting or inconvenient but not harmful to the health. Surge in such type of conditions and rising need to manage those effectually has led to the market growth for cancer supportive care drugs globally.
There has been huge demand for cancer supportive drugs which is likely to grow in forecast period. As per WHO, the growth in cancer cases is likely to raise by 75% in the next decade with more than 20 million new cancer cases. Likewise, according to stats provided by GLOBOCAN, 14.5Mn new cases of cancer were diagnosed in the year 2013 worldwide. Cancer is highly predominant in lower and middle income countries wherein they lack healthcare infrastructure facilities to effectively combat the condition. Similarly, 60% of the total worldwide deaths are caused due to cancer and its reported mainly in the lesser developed regions.
The market for cancer supportive care drugs is segmented based on cancer type, product, and regions. Based on cancer type the market is bifurcated into erythropoietin-stimulating agents (ESA), granulocyte-colony stimulating factors (G-CSF), bisphosphonates, antiemetics, non-steroidal anti-inflammatory drugs (NSAID), opioids, and other cancer supportive drugs. The segment for granulocyte-colony stimulating factors and erythropoietin-stimulating agents are likely to register high CARG in the forecast period as there has been a shift from biologics to biosimilars. This shift is backed by patent loss, high mortality, addiction, and major safety issues associated with narcotic agents.
By cancer type the market is segmented into lung cancer, breast cancer, prostate cancer, melanoma, and other cancers. Breast cancer is likely to grow at high CAGR in the forecast period. As per the stats provided by International Agency for Research on Cancer (IARC) published WHO in 2018, breast cancer is ranked among the fifth leading causes of deaths in women accounting for 630,000 deaths each year. High prevalence rate along with patent expiry of major drugs and investment in research and development of new products are some of the factors propelling market growth for this segment.
Regional segmentation includes the current and forecast demand for Asia Pacific, North America, Latin America, Europe, and Middle East & Africa with its further bifurcation into major countries. North America held major share of the market in 2018, due to the presence of leading industry players and availability of various FDA-approved products in this region. Besides number of biosimilars launched is low as compared to biosimilar penetration in the U.S. which is likely to increase due to twice the average pricing of biologics.
Some of the players included in cancer supportive care drugs market are Roche, Amgen, Merck, Helsinn Healthcare, Johnson & Johnson, Heron Pharma, and Tesaro.
The report segments the cancer supportive care drugs market as follows:
Global Cancer Supportive Care Drugs Market: Drug Class Segment Analysis
Global Cancer Supportive Care Drugs Market: Cancer Type Segment Analysis
Global Cancer Supportive Care Drugs Market: Regional Segment Analysis
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651